Why the study?
Photoplethysmography (PPG) in consumer smartwatches and smart rings has expanded well beyond heart-rate monitoring, pulse oximetry, and population-scale atrial fibrillation screening into emerging clinical applications.
What is the clinical reliability and evidence maturity of photoplethysmography in consumer wearables across emerging clinical applications beyond atrial fibrillation?
What is the clinical reliability and evidence maturity of photoplethysmography in consumer wearables across emerging clinical applications beyond atrial fibrillation?
Consumer-wearable photoplethysmography has strong evidence for resting heart-rate estimation and atrial fibrillation screening, but emerging applications like blood pressure, sleep apnoea, and SpO2 require cautious interpretation due to variable reliability, motion artefacts, and skin-tone bias.
May enable wearable OSA screening in adults ≥22; leaves open need for prospective validation before clinical adoption.
Introduction: Photoplethysmography (PPG) is an optical sensing technology embedded in many current consumer smartwatches and smart rings. Long used for heart-rate monitoring and pulse oximetry, PPG has more recently become the foundation for population-scale screening for atrial fibrillation. The clinical applications of PPG now extend well beyond rhythm monitoring. Method: A narrative literature review of English-language publications indexed in PubMed, Europe PMC, IEEE Xplore, and Google Scholar between January 2020 and May 2026 was conducted, using combinations of the search term photoplethysmography with application-specific search terms. Earlier foundational publications were included selectively where necessary. Discussion: Current evidence most strongly supports consumer-wearable PPG for resting heart-rate estimation and for atrial-fibrillation notification pathways with adjudicated electrocardiographic confirmation. SpO2 trending is conditionally supported in healthy, normoxaemic adults but is insufficient for clinical decision-making during desaturation, motion, low perfusion, or in populations under-represented in validation datasets. Cuffless blood-pressure estimation, heart-rate variability, sleep staging, and obstructive sleep apnoea screening show device-, context-, and reference-standard-dependent reliability. Non-invasive blood-glucose monitoring through smartwatches or smart rings should not be used for diabetes management and is the subject of an explicit FDA safety communication. Conclusion: Consumer-wearable PPG is a multifunctional clinical sensing platform whose evidence maturity differs sharply by application. Responsible deployment requires awareness of signal quality, motion artefact, skin-tone bias, regulatory authorisation status, and local validation, particularly in the Indonesian primary-care context.
No takes yet. Share an insight, caveat, or question.
Muhammad Rifqi Haikal (2026) studied Moderate to severe obstructive sleep apnea. Samsung Sleep Apnea Feature (over-the-counter mobile medical application on Samsung Galaxy Watch and Phone) vs. Clinical comparator device (e.g., polysomnography) was evaluated on Detection of signs of moderate to severe obstructive sleep apnea in the form of significant breathing disruptions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: